Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 237-241

  Xu, Dan yan ^a   Shu, Jun ^a   Huang, Quan yue ^a   Wasti, Binaya ^a   Chen, Chen ^a   Liu, Ling ^a   Zhao, Shui ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cardiovascular risk; Cholesterol; Inflammatory factor; Safety; Zhibitai

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; GELATINASE B; HEART ENZYME; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZHIBITAI; HEPTANOIC ACID DERIVATIVE; HERBACEOUS AGENT; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CHINESE MEDICINE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; INTENSIVE CARE; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRADITIONAL MEDICINE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; HYPERLIPIDEMIAS; METABOLISM; MIDDLE AGED;

AGED; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL; DRUGS, CHINESE HERBAL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MATRIX METALLOPROTEINASE 9; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; P-SELECTIN; PYRROLES; TRIGLYCERIDES;

EID: 77954314108     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.01.044     Document Type: Article

References (24)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 363:801-809.
2. Li J.J., Fang C.H. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses 2004, 63:100-102.
3. Tracy R.P. Inflammation in cardiovascular disease: cart, horse or both?. Circulation 1998, 97:2000-2002.
4. Li J.J. Inflammation: an important mechanism for different clinical entities of coronary artery diseases. Chin Med J 2005, 118:1817-1826.
5. Kwak B.R., Mach F. Statins inhibit leukocyte recruitment new evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 2001, 21:1256-1258.
6. Barnes P.M., Powell-Griner E., McFann K., Nahin R.L. Complementary and alternative medicine use among adults: United States 2002. Adv Data 2004, 343:1-19.
7. Yang Weng-ji, Fu Xiao-jie Comparing the lipid lowing effects between zhibituo and atorvastain. Zhong Guo Xian Dai Yi Yao Ke Ji 2003, 2:2-4.
8. Deedwania P., Stone P.H., Bairey Merz C.N., et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007, 115(February (6)):700-707. [Epub 2007 February 5].
9. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
10. Pedersen T.R., Faergeman O., Kastelein J.J.P., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
11. Li Shen-zi, Li Ping-tu Comparing the effects of simvastatin with zhibituo on lipoprotein abnormality. Fu Jian Yi Yao Za Zhi 2006, 28:139-140.
12. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
13. Becker D.J., Gordon R.Y., Morris P.B., et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc 2008, 83:758-764.
14. Ma J., Li Y., Ye Q., et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000, 48(11):5220-5225.
15. Patrick L., Uzick M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev 2001, 6(3):248-271.
16. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
17. Baldassarre D., Porta B., Camera M., et al. Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis 2009, 19(September (7)):481-490.
18. Peason T.A., Mensah G.A., Alexander R.W., et al. Marder of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from centers for Disease control and prevention and the American Heart Association. Circulation 2003, 107:499-511.
19. Zhao S.P., Xu D.Y. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb Res 2000, 100:501-510.
20. Haider N., Hartung D., Fujimoto S., et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nucl Cardiol 2009, 16:753-762.
21. Chang W.T., Dao J., Shao Z.H. Hawthorn: potential roles in cardiovascular disease. Am J Chin Med 2005, 33(1):1-10.
22. Qian Jia-Jun Serial studies of the effects of Alisma L. on atherosclerosis(1)-progression of the research of Alisma L. J Beijing Univ Trad Chin Med 1991, 14:42.
23. Li XY, Weng HY, Cai D. Influence of Shenlinbaizhu Powder on 30 patients with metabolic syndrome. CJGMCM, 2009, 24(March(3)):496-7.
24. Li J.J., Lu Z.L., Kou W.R., et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol 2009, 49:947-956.